Vertex Pharma Acquires ViroChem For $395M

Law360, New York (March 16, 2009, 12:00 AM EDT) -- In a strategic move meant to strengthen its hepatitis C treatment pipeline, Vertex Pharmaceuticals Inc. has acquired Canada-based ViroChem Pharmaceuticals Inc. for around $395 million, including $100 million in cash.

Vertex completed the share purchase transaction on Thursday, according to a press release. ViroChem shareholders received $100 million in cash and 10.73 million shares of Vertex common stock, the company said.

Vertex stock was trading at $27.15 per share on March 11, the company disclosed in a filing with the U.S. Securities and Exchange Commission on...
To view the full article, register now.